Immunomedics Stock Price, News & Analysis (NASDAQ:IMMU)

$16.38 +0.16 (+0.99 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$16.38
Today's Range$16.23 - $17.06
52-Week Range$4.73 - $18.93
Volume1.04 million shs
Average Volume2.50 million shs
Market Capitalization$2.49 billion
P/E Ratio-8.81
Dividend YieldN/A
Beta1.5

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:IMMU
CUSIP45290710
Phone+1-973-6058200

Debt

Debt-to-Equity Ratio1.20%
Current Ratio1.26%
Quick Ratio1.26%

Price-To-Earnings

Trailing P/E Ratio-8.80645161290322
Forward P/E Ratio-17.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.09 million
Price / Sales878.79
Cash FlowN/A
Price / CashN/A
Book Value$0.10 per share
Price / Book163.80

Profitability

Trailing EPS($1.86)
Net Income$-153,200,000.00
Net Margins-7,187.83%
Return on EquityN/A
Return on Assets-76.04%

Miscellaneous

Employees138
Outstanding Shares165,780,000

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings data on Thursday, February, 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.03. The biopharmaceutical company had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.70 million. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2018?

3 equities research analysts have issued 12-month price targets for Immunomedics' shares. Their forecasts range from $15.00 to $27.00. On average, they anticipate Immunomedics' share price to reach $21.00 in the next year. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in January. As of January 31st, there was short interest totalling 28,169,474 shares, an increase of 2.4% from the January 12th total of 27,496,613 shares. Based on an average daily volume of 2,437,956 shares, the short-interest ratio is presently 11.6 days. Approximately 20.7% of the shares of the company are sold short.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

  • Behzad Aghazadeh Ph.D., Independent Chairman of the Board (Age 46)
  • Michael F. Pehl, President, Chief Executive Officer, Director (Age 52)
  • Michael R. Garone, Chief Financial Officer, Vice President - Finance (Age 59)
  • David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director (Age 79)
  • Brendan Delaney, Chief Commercial Officer
  • Cynthia L. Sullivan, Director (Age 61)
  • Scott A. Canute, Independent Director (Age 57)
  • Peter Barton Hutt, Independent Director (Age 82)
  • Khalid Islam Ph.D., Independent Director (Age 61)
  • Brian A. Markison, Lead Independent Director (Age 58)

Who owns Immunomedics stock?

Immunomedics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.96%), ArrowMark Colorado Holdings LLC (3.15%), Palo Alto Investors LLC (2.88%), Jennison Associates LLC (1.20%), Victory Capital Management Inc. (0.73%) and Geode Capital Management LLC (0.60%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Renaissance Technologies LLC, Deutsche Bank AG, Nexthera Capital LP, Gotham Asset Management LLC, Chicago Equity Partners LLC, EAM Investors LLC and Sphera Funds Management LTD.. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, ArrowMark Colorado Holdings LLC, Victory Capital Management Inc., Franklin Resources Inc., BlackRock Inc., Lyon Street Capital LLC, Ardsley Advisory Partners and Guggenheim Capital LLC. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of Immunomedics stock can currently be purchased for approximately $16.38.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $2.49 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 the American Rd, MORRIS PLAINS, NJ 07950-2460, United States. The biopharmaceutical company can be reached via phone at +1-973-6058200 or via email at [email protected]


MarketBeat Community Rating for Immunomedics (IMMU)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  364
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immunomedics (NASDAQ:IMMU) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.00$15.50$15.50$13.00
Price Target Upside: 15.96% upside32.93% upside32.93% upside62.91% upside

Immunomedics (NASDAQ:IMMU) Consensus Price Target History

Price Target History for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ:IMMU) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Jefferies GroupBoost Price TargetBuy$22.00 -> $27.00MediumView Rating Details
7/24/2017CowenReiterated RatingOutperform$15.00LowView Rating Details
5/5/2017Wells Fargo & CoUpgradeMarket Perform -> OutperformHighView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Immunomedics (NASDAQ:IMMU) Earnings History and Estimates Chart

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ IMMU) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q1 2018($0.10)($0.16)$0.90 million$0.69 millionViewN/AView Earnings Details
8/16/2017Q4 2017($0.12)($0.25)$0.75 million$0.64 millionViewN/AView Earnings Details
5/10/2017Q3 2017($0.13)($0.22)$0.90 million$1.32 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
11/4/2013Q1 2014($0.10)($0.05)$1.51 million$5.50 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
2/7/2013Q2 2013($0.09)($0.07)ViewN/AView Earnings Details
11/8/2012Q1 2013($0.08)($0.10)ViewN/AView Earnings Details
8/23/2012Q4 2012($0.08)($0.10)ViewN/AView Earnings Details
5/8/2012Q3 2012($0.08)($0.10)ViewN/AView Earnings Details
2/8/2012Q2 2012($0.08)$0.27ViewN/AView Earnings Details
11/4/2011Q1 2012($0.08)($0.07)ViewN/AView Earnings Details
8/24/2011Q4 2011($0.06)$0.03ViewN/AView Earnings Details
5/10/2011Q3 2011($0.06)($0.10)ViewN/AView Earnings Details
2/4/2011Q2 2011($0.08)($0.05)ViewN/AView Earnings Details
11/4/2010Q1 2011($0.07)($0.09)ViewN/AView Earnings Details
8/26/2010Q4 2010($0.08)$0.01ViewN/AView Earnings Details
5/10/2010Q3 2010($0.09)$0.05ViewN/AView Earnings Details
2/2/2010Q2 2010$0.03$0.01ViewN/AView Earnings Details
11/6/2009Q1 2010$0.43$0.42ViewN/AView Earnings Details
8/27/2009Q4 2009$0.01$0.01ViewN/AView Earnings Details
5/11/2009Q3 2009($0.01)$0.01ViewN/AView Earnings Details
2/9/2009Q2 2009($0.01)$0.04ViewN/AView Earnings Details
11/7/2008Q1 2009($0.03)ViewN/AView Earnings Details
8/28/2008Q4 2008($0.08)($0.09)ViewN/AView Earnings Details
5/7/2008Q3 2008($0.08)ViewN/AView Earnings Details
2/7/2008Q2 2008($0.09)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Immunomedics (NASDAQ:IMMU) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.19)($0.19)($0.19)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Immunomedics (NASDAQ:IMMU)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Immunomedics (NASDAQ IMMU) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 72.69%
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ IMMU) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2017Brian A MarkisonDirectorSell8,390$11.89$99,757.1099,178View SEC Filing  
11/15/2017Behzad AghazadehInsiderBuy1,325,000$10.47$13,872,750.00View SEC Filing  
11/14/2017Venbio Select Advisor LlcDirectorBuy1,150,000$10.39$11,948,500.00View SEC Filing  
9/1/2017David M. GoldenbergInsiderSell20,000$12.64$252,800.00View SEC Filing  
8/28/2017Cynthia L. GoldenbergDirectorSell40,000$10.72$428,800.00View SEC Filing  
8/23/2017Cynthia L. GoldenbergDirectorSell40,000$9.24$369,600.00View SEC Filing  
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.0055,848View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.0082,474View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70650,396View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42703,029View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.802,602,063View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00703,029View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.002,602,063View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31703,029View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.982,602,063View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.0022,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Immunomedics (NASDAQ IMMU) News Headlines

Source:
DateHeadline
Immunomedics (IMMU) Upgraded by TheStreet to C-Immunomedics (IMMU) Upgraded by TheStreet to C-
www.americanbankingnews.com - February 18 at 9:22 PM
Zacks Investment Research Downgrades Immunomedics (IMMU) to SellZacks Investment Research Downgrades Immunomedics (IMMU) to Sell
www.americanbankingnews.com - February 17 at 6:56 AM
Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare ConferenceImmunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 8:20 AM
Reviewing Immunomedics (IMMU) and Arsanis (ASNS)Reviewing Immunomedics (IMMU) and Arsanis (ASNS)
www.americanbankingnews.com - February 15 at 3:18 AM
Blog Exposure - FDA Accepts Amicus Therapeutics’ NDA for Migalastat for Treatment of Fabry DiseaseBlog Exposure - FDA Accepts Amicus Therapeutics’ NDA for Migalastat for Treatment of Fabry Disease
finance.yahoo.com - February 14 at 9:33 AM
Immunomedics (IMMU) Raised to "Buy" at BidaskClubImmunomedics (IMMU) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - February 11 at 8:10 AM
Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by BrokeragesImmunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 10 at 1:58 PM
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate UpdateImmunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update
finance.yahoo.com - February 9 at 9:35 AM
Immunomedics reports 2Q lossImmunomedics reports 2Q loss
finance.yahoo.com - February 9 at 9:35 AM
Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018
finance.yahoo.com - February 6 at 9:31 AM
Analyzing Ironwood Pharmaceuticals (IRWD) and Immunomedics (IMMU)Analyzing Ironwood Pharmaceuticals (IRWD) and Immunomedics (IMMU)
www.americanbankingnews.com - January 31 at 5:12 PM
Immunomedics (IMMU) Price Target Raised to $27.00Immunomedics (IMMU) Price Target Raised to $27.00
www.americanbankingnews.com - January 28 at 5:34 PM
BidaskClub Upgrades Immunomedics (IMMU) to Strong-BuyBidaskClub Upgrades Immunomedics (IMMU) to Strong-Buy
www.americanbankingnews.com - January 28 at 8:54 AM
Contrasting Celator Pharmaceuticals (CPXX) and Immunomedics (IMMU)Contrasting Celator Pharmaceuticals (CPXX) and Immunomedics (IMMU)
www.americanbankingnews.com - January 28 at 7:18 AM
Q3 2018 EPS Estimates for Immunomedics, Inc. Lifted by Analyst (IMMU)Q3 2018 EPS Estimates for Immunomedics, Inc. Lifted by Analyst (IMMU)
www.americanbankingnews.com - January 26 at 10:22 AM
Interesting IMMU Put And Call Options For March 16thInteresting IMMU Put And Call Options For March 16th
www.nasdaq.com - January 24 at 4:17 PM
Immunomedics, Inc. (IMMU) Given Average Recommendation of "Buy" by BrokeragesImmunomedics, Inc. (IMMU) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 16 at 2:08 PM
Short Sellers Fueling Runaway Bull Market By Racing To Buy Back StocksShort Sellers Fueling Runaway Bull Market By Racing To Buy Back Stocks
www.forbes.com - January 15 at 3:27 PM
Short Interest in Immunomedics, Inc. (IMMU) Expands By 6.3%Short Interest in Immunomedics, Inc. (IMMU) Expands By 6.3%
www.americanbankingnews.com - January 12 at 3:14 AM
BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate CancerBRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer
www.reuters.com - January 11 at 8:50 AM
Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate CancerImmunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer
finance.yahoo.com - January 11 at 8:50 AM
Today’s Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome TherapeuticsToday’s Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics
finance.yahoo.com - January 10 at 9:28 AM
Immunomedics (IMMU) Enters Royalty Funding and Stock Purchase Agreements with Royalty Pharma Worth $250MImmunomedics (IMMU) Enters Royalty Funding and Stock Purchase Agreements with Royalty Pharma Worth $250M
www.streetinsider.com - January 9 at 9:46 AM
Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million - GlobeNewswire (press release)Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million - GlobeNewswire (press release)
globenewswire.com - January 8 at 3:32 PM
Immunomedics (IMMU) Downgraded by ValuEngine to SellImmunomedics (IMMU) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - January 5 at 11:22 PM
Immunomedics to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Immunomedics to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 5 at 9:24 AM
Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceImmunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:15 AM
Immunomedics (IMMU) and Its Rivals Financial ReviewImmunomedics (IMMU) and Its Rivals Financial Review
www.americanbankingnews.com - January 2 at 5:28 AM
Head to Head Contrast: Immunomedics (IMMU) & Its PeersHead to Head Contrast: Immunomedics (IMMU) & Its Peers
www.americanbankingnews.com - January 1 at 5:10 PM
Harry Boxer: These two marijuana stocks are climbing higherHarry Boxer: These two marijuana stocks are climbing higher
finance.yahoo.com - December 28 at 3:01 PM
Immunomedics (IMMU) Upgraded to Buy by BidaskClubImmunomedics (IMMU) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - December 22 at 8:18 PM
ETFs with exposure to Immunomedics, Inc. : December 22, 2017ETFs with exposure to Immunomedics, Inc. : December 22, 2017
finance.yahoo.com - December 22 at 3:49 PM
Immunomedics, Inc. (IMMU) Given Average Recommendation of "Buy" by AnalystsImmunomedics, Inc. (IMMU) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 22 at 2:50 PM
BlackBerry Among Four Stocks Breaking OutBlackBerry Among Four Stocks Breaking Out
finance.yahoo.com - December 21 at 3:29 PM
Passive Investors And Their Role In Activism For 2018Passive Investors And Their Role In Activism For 2018
www.forbes.com - December 21 at 9:04 AM
First Week of August 2018 Options Trading For Immunomedics (IMMU)First Week of August 2018 Options Trading For Immunomedics (IMMU)
www.nasdaq.com - December 20 at 3:26 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of ... - PR Newswire (press release)SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of ... - PR Newswire (press release)
www.prnewswire.com - December 14 at 9:00 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - December 13 at 9:12 AM
ETFs with exposure to Immunomedics, Inc. : December 11, 2017ETFs with exposure to Immunomedics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:25 PM
Immunomedics (IMMU) & Its Peers Head to Head ReviewImmunomedics (IMMU) & Its Peers Head to Head Review
www.americanbankingnews.com - December 10 at 5:20 PM
Immunomedics' Data Is Good News for Seattle Genetics, TooImmunomedics' Data Is Good News for Seattle Genetics, Too
finance.yahoo.com - December 8 at 9:10 AM
Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017
finance.yahoo.com - December 8 at 9:10 AM
Immunomedics (IMMU) Updated Results With Sacituzumab Govitecan In Patients With Relapsed Or Refractory mTNBCImmunomedics (IMMU) Updated Results With Sacituzumab Govitecan In Patients With Relapsed Or Refractory mTNBC
www.streetinsider.com - December 7 at 3:29 PM
Why Immunomedics, Inc. Is Soaring Today - Motley FoolWhy Immunomedics, Inc. Is Soaring Today - Motley Fool
www.fool.com - December 7 at 9:08 AM
Today’s Research Reports on Stocks to Watch: Immunomedics and Valeant PharmaceuticalsToday’s Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals
finance.yahoo.com - December 7 at 9:08 AM
Why Immunomedics, Inc. Is Soaring TodayWhy Immunomedics, Inc. Is Soaring Today
finance.yahoo.com - December 7 at 9:08 AM
Immunomedics rallies 17% ahead of data release on lead candidate IMMU-132Immunomedics rallies 17% ahead of data release on lead candidate IMMU-132
seekingalpha.com - December 6 at 12:23 PM
Immunomedics (IMMU) Rating Lowered to Sell at ValuEngineImmunomedics (IMMU) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 4 at 9:38 PM
Jim Cramer Gives His Opinion IDT, Sherwin-Williams And Immunomedics - BenzingaJim Cramer Gives His Opinion IDT, Sherwin-Williams And Immunomedics - Benzinga
www.benzinga.com - December 1 at 11:46 AM
ETFs with exposure to Immunomedics, Inc. : November 30, 2017ETFs with exposure to Immunomedics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:27 PM

SEC Filings

Immunomedics (NASDAQ:IMMU) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Immunomedics (NASDAQ:IMMU) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Immunomedics (NASDAQ IMMU) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.